|
Patient demographics
| | |
|
Age, years
|
60.9 ± 10.3
|
62.3 ± 10.4
|
|
Males
|
185 (94%)
|
287 (94%)
|
|
Race/ethnicity
| | |
|
Caucasian, non-Hispanic
|
159 (81%)
|
248 (81%)
|
|
Non-Caucasian, Hispanic
|
7 (4%)
|
8 (3%)
|
|
Black, non-Hispanic
|
27 (14%)
|
45 (15%)
|
|
American Indian or Pacific Islander
|
4 (2%)
|
4 (1%)
|
|
RA drug initiated
| | |
|
Abatacept
|
9 (5%)
|
9 (3%)
|
|
Adalimumab
|
74 (38%)
|
74 (24%)
|
|
Etanercept
|
60 (31%)
|
60 (20%)
|
|
Infliximab
|
34 (17%)
|
34 (11%)
|
|
Rituximab
|
20 (10%)
|
20 (7%)
|
|
Hydroxychloroquine
|
n/a
|
63 (21%)
|
|
Leflunomide
|
n/a
|
20 (7%)
|
|
Sulfasalazine
|
n/a
|
25 (8%)
|
|
RA-related characteristics
| | |
|
DAS28
|
5.0 ± 1.5
|
4.9 ± 1.6
|
|
CDAI (0-76)
|
30.2 ± 16.3
|
27.5 ± 15.2
|
|
Physician global (0 to 100)
|
51.0 ± 22.1
|
50.3 ± 22.6
|
|
Patient global (0 to 100)
|
57.4 ± 25.2
|
54.8 ± 24.2
|
|
Tender joint count (0 to 28)
|
9.6 ± 8.6
|
8.5 ± 7.9
|
|
Swollen joint count (0 to 28)
|
7.9 ± 7.2
|
7.8 ± 6.6
|
|
MDHAQ (0 to 3)
|
1.2 ± 0.6
|
1.2 ± 0.6
|
|
ESR, mm/hour
|
27.9 ± 23.3
|
29.9 ± 24.6
|
|
CRP, mg/dL
|
1.9 ± 2.4
|
2.1 ± 2.5
|
